Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 49Neoplasm Metastasis 46Multiple Myeloma 40Breast Neoplasms 33Prostatic Neoplasms 30Colorectal Neoplasms 27Lymphoma 26Lung Neoplasms 26Leukemia, Lymphocytic, Chronic, B-Cell 24Pancreatic Neoplasms 23Myelodysplastic Syndromes 22Lymphoma, Large B-Cell, Diffuse 21Triple Negative Breast Neoplasms 19Ovarian Neoplasms 17Melanoma 17Carcinoma, Non-Small-Cell Lung 17Burkitt Lymphoma 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Neoplasms 15Carcinoma, Renal Cell 15Leukemia, Myelomonocytic, Chronic 13Glioma 13Neuroblastoma 12Lymphoma, Mantle-Cell 12Lymphoma, Follicular 12Sarcoma 11Lymphoma, Non-Hodgkin 11Fallopian Tube Neoplasms 11Endometrial Neoplasms 11Myeloproliferative Disorders 10

Interventions

fludarabine phosphate 2Cyclophosphamide 2pevonedistat 1ibrutinib 1Specimen Handling 1Pharmacogenomic Variants 1Leukapheresis 1Etoposide 1Blood Component Removal 1Biopsy 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Prolymphocytic, B-Cell × Biopsy × 1 year × Clear all
NCT05418088 2026-05-29

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Ohio State University Comprehensive Cancer Center

Phase 1 Recruiting
54 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Prolymphocytic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡